Please login to the form below
Oesophageal cancer
This page shows the latest Oesophageal cancer news and features for those working in and with pharma, biotech and healthcare.
Bristol Myers Squibb’s Opdivo recommended by NICE for rare gastroesophageal cancers
By attaching to PD-1, Opdivo blocks its action and allows the body’s immune system to continue to attack the gastric, oesophageal or gastro-oesophageal junction cancer cells. ... recommend this innovative treatment for people with these rare forms of
Latest news
-
University of Cambridge launches Early Cancer Institute for complex cancers
The test has been proven to detect oesophageal cancer in time for it to be treated, and involves patients being administered a pill that dissolves into a sponge. ... Given that only one in eight oesophageal cancer patients (12%) survive for ten or more
-
BeiGene announces positive phase 3 trial results for liver cancer treatment
There were more than 900, 000 new cases in 2020 of the most common type of primary liver cancer – unresectable hepatocellular carcinoma. ... Japan. Last month, Novartis announced positive results from a phase 3 trial showing tislelizumab plus
-
Novartis announces positive phase 3 trial results for advanced oesophageal cancer
Novartis has announced positive results from a phase 3 trial showing tislelizumab plus chemotherapy significantly improved overall survival (OS) for patients with advanced oesophageal cancer, regardless of PD-L1 status. ... The treatment is currently
-
AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
Small cell lung cancer accounts for 15% of all lung cancers and has a poor prognosis. ... tract cancer, oesophageal cancer, gastric and gastroesophageal cancer, cervical cancer, ovarian cancer, endometrial cancer, and other solid tumours.
-
Merck’s Keytruda gains two more approvals in Japan
The second indication is in colorectal cancer, targeting unresectable, advanced or recurrent high microsatellite instability (MSI-H) colorectal cancer. ... In the US alone, it is indicated for cancers including melanoma, non-small cell lung cancer,
More from news
Approximately 8 fully matching, plus 21 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma companies to watch
The company’s biggest play last year was licensing Daiichi Sankyo’s cancer candidate trastuzumab deruxtecan for an eyewatering. ... Other important read-outs in first-line kidney, oesophageal and gastric cancer are also due this year, as well as
-
Chinese biotech’s global ambitions
has just achieved a landmark approval in China for its own ‘home-grown’ cancer medicine. ... Tislelizumab is in global phase III trials in a number of tumour types, including non-small cell lung cancer, hepatocellular carcinoma and oesophageal
-
Deal Watch March 2016
Acquisition of royalty rights. $1, 140. Blueprint Medicines/ Roche. Small molecules targeting kinases for cancer immunotherapy. ... Collaboration – marketing &distribution. $171. AVEO Oncology/ CANbridge Life Sciences. AV-203; ErbB3 (HER3) inhibitory
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- PMGroup announces launch of new recruitment platform PharmaRole
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- BioNTech reveals plans to spend about €1bn more on research and development this year
- AstraZeneca’s mild combination asthma reliever approved in UK
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- MHRA to introduce new UK clinical trials framework
- Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
- Inizio appoints Stefanie Christmas as global head of DE&I
- The Considered appoints Bam Zahraie as chief experience officer
PMHub
Origins - The Patient Focused Specialists
Origins creates and delivers patient focused strategy, insights, data and solutions, which guides pharma and biotech companies to improve value...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
